Novo Aims to Launch More Than Five Blockbuster Products by 2030
Jakarta (ANTARA) — Global pharmaceutical company Novo Nordisk aims to launch more than five products with high sales potential (multi-blockbusters) by 2030, as part of a strategy to strengthen its portfolio and drive sustainable business growth.
The target was announced at the 2026 Capital Markets Day (CMD), held in London, United Kingdom, on 12 October 2026. The event also outlined the company’s strategic direction through to 2030.
Novo said its strategy rests on three main priorities: expanding its product portfolio, driving sustainable growth and delivering attractive returns to shareholders.
Through this portfolio development, Novo is targeting sales of more than 150 billion Danish kroner (DKK) by 2035 from the flagship products planned for launch by 2030.
The company also aims to have at least five Phase 3 clinical development programmes in obesity and diabetes, and five more in other therapeutic areas.
In terms of business growth, Novo is targeting average annual revenue growth, or compound annual growth rate (CAGR), from 2026 to 2030 in line with its peers in the pharmaceutical industry.
To support these targets, Novo plans to increase production capacity to broaden access to obesity treatments, including expanding its service capacity by up to tenfold through oral GLP-1 therapies.
The company aims to serve more than 60 million patients worldwide by 2030.
Alongside product development and expanded production capacity, Novo is seeking to keep its operating margin broadly stable while maintaining an attractive dividend per share for shareholders.
At the forum, Novo’s senior management also presented its research and development strategy, plans to strengthen its business in the United States and international markets, and preparations for global manufacturing and supply chains.
These strategic steps are aligned with the company’s transformation, which includes introducing a new identity centred on the message “Lasting Health Starts Now” and adopting the single name “Novo”.
The company is also refreshing its corporate culture through “The Novo Way”, with the aim of creating a more focused, agile and impact-oriented organisation.
Through this transformation, Novo aims to strengthen its competitiveness while broadening public access to healthcare services and treatments in countries around the world.
Source: jawawa.id (https://jawawa.id/newsitem/novo-aims-to-launch-more-than-five-blockbuster-products-by-2030-1791881744)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5783414/novo-targetkan-luncurkan-lebih-dari-lima-produk-unggulan-hingga-2030), translated from Indonesian